Neumora Therapeutics (NMRA) Financials

Neumora Therapeutics (NASDAQ: NMRA) remains a pre-revenue biotechnology company with substantial operating losses, although its latest quarter showed improved expense control and a slower cash burn. Revenue has been reported at zero in every income statement period provided, leaving the company dependent on cash reserves, financing and potential future product development milestones.

In Q2 2026, total operating expenses declined to $42.2 million from $52.9 million in Q1 2026 and $58.5 million in Q4 2025. Research and development spending fell to $29.3 million from $38.6 million in Q1, while selling, general and administrative costs decreased to $12.9 million from $14.3 million. The lower spending helped narrow the net loss to $43.1 million, compared with losses of $53.5 million in Q1 2026 and $59.5 million in Q4 2025.

• Operating expenses are trending lower. Q2 2026 expenses were approximately 20% below Q1 2026 and 28% below Q4 2025, which could extend the company’s cash runway if the lower spending level is sustained.
• Quarterly cash burn improved. Cash used in operating activities decreased to $39.5 million in Q2 2026 from $46.4 million in Q1 2026 and $49.2 million in Q4 2025.
• Liquidity remains adequate in the near term. NMRA held $116.8 million of cash at June 30, 2026, compared with $27.8 million of current liabilities. The company also generated $9.3 million of net financing cash during the quarter.
• Interest income continues to provide a modest offset. Q2 interest and investment income totaled $935,000, partially reducing the impact of operating losses, although this benefit is declining as cash and investments have been consumed.
• The company remains entirely pre-revenue. No revenue or gross profit was reported in the periods provided, so the investment case continues to depend primarily on clinical progress and eventual commercialization rather than current operating performance.
• Near-term cash runway is difficult to estimate precisely. Q2 cash of $116.8 million equates to roughly three quarters of Q2 operating cash burn, but future research spending, financing activity and clinical development costs could materially change that estimate.
• Cash reserves have fallen sharply over the longer term. Cash and equivalents declined from $182.9 million in Q1 2024 to $116.8 million in Q2 2026, while total assets fell from $450.2 million to $125.2 million over the same comparison.
• Losses and negative operating cash flow remain persistent. NMRA has reported losses in every income statement period supplied, and operating cash flow has remained negative in each cash-flow period shown.
• Debt has increased substantially. Long-term debt rose to $52.9 million in Q2 2026 from $19.6 million in Q3 2025. Interest expense of $1.8 million in Q2 further adds to the company’s cash requirements.
• Shareholder dilution is a continuing risk. Weighted-average basic shares increased to 185.2 million in Q2 2026 from 161.5 million in Q1 2024. Additional equity financing may be required if operating losses continue, which could dilute existing shareholders.

Overall, NMRA’s latest quarter offers a mixed picture. The reduction in research and administrative spending and the improvement in quarterly cash burn are constructive, but the company still has no revenue, continues to consume tens of millions of dollars each quarter and has substantially less cash than it held two years earlier. Retail investors should closely monitor clinical progress, future financing activity, debt levels and whether the recent expense reductions can be maintained without slowing development.